Ionis Pharmaceuticals 배당금 및 환매

배당금 기준 확인 0/6

Ionis Pharmaceuticals 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-10.5%

환매 수익률

총 주주 수익률	-10.5%
미래 배당 수익률	0%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 IONS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: IONS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Ionis Pharmaceuticals 시장 대비 배당 수익률

IONS 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (IONS)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Biotechs)	2.3%
애널리스트 예측 (IONS) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IONS 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IONS 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IONS 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: IONS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Ionis Pharmaceuticals 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen